1. Home
  2. EVH vs CHRS Comparison

EVH vs CHRS Comparison

Compare EVH & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evolent Health Inc

EVH

Evolent Health Inc

HOLD

Current Price

$3.02

Market Cap

344.8M

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.66

Market Cap

291.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVH
CHRS
Founded
2011
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
344.8M
291.5M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
EVH
CHRS
Price
$3.02
$1.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
4
Target Price
$7.93
$5.51
AVG Volume (30 Days)
3.1M
1.4M
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
1.43
Revenue
$907,957,000.00
N/A
Revenue This Year
$33.03
$88.67
Revenue Next Year
$16.03
$28.64
P/E Ratio
N/A
$1.14
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.72
52 Week High
$11.92
$2.62

Technical Indicators

Market Signals
Indicator
EVH
CHRS
Relative Strength Index (RSI) 46.26 44.32
Support Level $2.53 $1.55
Resistance Level $4.20 $1.75
Average True Range (ATR) 0.26 0.11
MACD 0.00 -0.01
Stochastic Oscillator 44.77 22.09

Price Performance

Historical Comparison
EVH
CHRS

About EVH Evolent Health Inc

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: